A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models

Vaccine

Volumn 30, Issue 28, 2012, Pages 4249-4258

  Tian, Jing Hui ^a,e   Fuhrmann, Steven R ^a,c   Kluepfel Stahl, Stefanie ^a,d   Carman, Robert J ^b   Ellingsworth, Larry ^a   Flyer, David C ^a,e  

^a Intercell USA   (United States)

^b TECHLAB INC   (United States)

^c INTREXON CORPORATION   (United States)

^d Emergent Biosolutions   (United States)

^e NOVAVAX INC   (United States)

Author keywords

Clostridium difficile; Clostridium difficile associated disease; Fusion protein; Toxin; Vaccine

Indexed keywords

BACTERIAL VACCINE; CARBOXY TERMINAL TOXIN A AND B FUSION PROTEIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; HYBRID PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HAMSTER; HAPLORHINI; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTITOXINS; BACTERIAL PROTEINS; BACTERIAL TOXINS; BACTERIAL VACCINES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CRICETINAE; ENTEROTOXINS; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; MESOCRICETUS; MICE; MICE, INBRED C57BL; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; VACCINES, SYNTHETIC;

EID: 84861661669     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.045     Document Type: Article

References (38)

1. Redelings M.D., Sorvillo F., Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007, 13(September (9)):1417-1419.
2. Warny M., Pepin J., Fang A., Killgore G., Thompson A., Brazier J., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366(September (9491)):1079-1084.
3. Kyne L., Warny M., Qamar A., Kelly C.P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000, 342(February (6)):390-397.
4. Samore M.H. Epidemiology of nosocomial Clostridium difficile diarrhoea. J Hosp Infect 1999, (December (43 Suppl.)):S183-S190.
5. Fekety R., McFarland L.V., Surawicz C.M., Greenberg R.N., Elmer G.W., Mulligan M.E. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997, 24(March (3)):324-333.
6. Voth D.E., Ballard J.D. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005, 18(April (2)):247-263.
7. Dove C.H., Wang S.Z., Price S., Phelp C.J., Lyerly D., Wilkins T.D., Johnson JL Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun 1990, 58(February (2)):480-488.
8. von Eichel-Streiber C., Laufenberg-Feldmann R., Sartingen S., Schulze J., Sauerborn M Comparative sequence analysis of the Clostridium difficile toxins A and B. Mol Gen Genet 1992, 233(May (1-2)):260-268.
9. Tucker K.D., Wilkins T.D. Toxin A of Clostridium difficile binds to the human carbohydrate antigens I, X, and Y. Infect Immun 1991, 59(January (1)):73-78.
10. Pothoulakis C., Gilbert R.J., Cladaras C., Castagliuolo I., Semenza G., Hitti Y., et al. Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin A. J Clin Invest 1996, 98(August (3)):641-649.
11. Demarest S.J., Salbato J., Elia M., Zhong J., Morrow T., Holland T., et al. Structural characterization of the cell wall binding domains of Clostridium difficile toxins A and B; evidence that Ca2+ plays a role in toxin A cell surface association. J Mol Biol 2005, 346(March (5)):1197-1206.
12. Ho J.G.S., Greco A., Rupnik M., Ng K. Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A. PNAS 2005, 102(December (51)):18373-18378.
13. Kim P.H., Iaconis J.P., Rolfe R.D. Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun 1987, 55(December (12)):2984-2992.
14. Lyerly D.M., Johnson J.L., Frey S.M., Wilkins TD Vaccination against lethal Clostridium difficile enterocolitis with a nontoxic recombinant peptide of toxin A. Curr Microbiol 1990, 21:29-32.
15. Torres J.F., Lyerly D.M., Hill J.E., Monath T.P. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun 1995, 63(December (12)):4619-4627.
16. Giannasca P.J., Zhang Z.X., Lei W.D., Boden J.A., Giel M.A., Monath T.P., et al. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun 1999, 67(February (2)):527-538.
17. Ryan E.T., Butterton J.R., Smith R.N., Carroll P.A., Crean T.I., Calderwood S.B. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain. Infect Immun 1997, 65(July (7)):2941-2949.
18. Ward S.J., Douce G., Dougan G., Wren B.W. Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile. Infect Immun 1999, 67(October (10)):5124-5132.
19. Lyerly D.M., Bostwick E.F., Binion S.B., Wilkins T.D. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun 1991, 59(June (6)):2215-2218.
20. Kelly C.P., Pothoulakis C., Vavva F., Castagliuolo I., Bostwick E.F., O'Keane J.C., et al. Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob Agents Chemother 1996, 40(February (2)):373-377.
21. Kink J.A., Williams J.A. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 1998, 66(May (5)):2018-2025.
22. Babcock G.J., Broering T.J., Hernandez H.J., Mandell R.B., Donahue K., Boatright N., et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 2006, 74(November (11)):6339-6347.
23. Leav B.A., Blair B., Leney M., Knauber M., Reilly C., Lowy I., et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010, 28(January (4)):965-969.
24. Kyne L., Warny M., Qamar A., Kelly C.P. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001, 357(January (9251)):189-193.
25. Leung D.Y., Kelly C.P., Boguniewicz M., Pothoulakis C., LaMont J.T., Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991, 118(April (4 Pt 1)):633-637.
26. Salcedo J., Keates S., Pothoulakis C., Warny M., Castagliuolo I., LaMont J.T., et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 1997, 41(September (3)):366-370.
27. Wilcox M.H. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 2004, 53(May (5)):882-884.
28. Frey S.M., Wilkins T.D. Localization of two epitopes recognized by monoclonal antibody PCG-4 on Clostridium difficile toxin A. Infect Immun 1992, 60(June (6)):2488-2492.
29. Gardiner D.F., Rosenberg T., Zaharatos J., Franco D., Ho D.D. A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine 2009, 27(June (27)):3598-3604.
30. Lowy I., Molrine D.C., Leav B.A., Blair B.M., Baxter R., Gerding D.N., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010, 362(January (3)):197-205.
31. Carman R.J., Wickham K.N., Chen L., Lawrence A.M., Boone J.H., Wilkins T.D., et al. Glutamate dehydrogenase (GDH) is highly conserved among Clostridium difficile ribotypes. J Clin Microbiol 2012 Feb 1, [Epub ahead of print].
32. Lyerly D.M., Saum K.E., MacDonald D.K., Wilkins T.D. Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun 1985, 47(February (2)):349-352.
33. Alfa M.J., Kabani A., Lyerly D., Moncrief S., Laurie M., Neville L.M., et al. Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000, 38(July (7)):2706-2714.
34. Siddiqui F., O'Connor J.R., Nagaro K., Chekinis A., Sambol S.P., Vedantam G., et al. Vaccination with parental toxoid B protects hamsters against a lethal challenge with toxin A-negative, toxin B-positive Clostruidium difficile but does not prevent colonization. J Infect Dis 2012, 201(January (1)):128-133.
35. Lyras D., O'Connor J.R., Howarth P.M., Sambol S.P., Carter G.P., Phumoonna T., et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009, 458(April (7242)):1176-1179.
36. Kuehne S.A., Cartman S.T., Minton N.P. Both, toxin A and toxin B are important in Clostridium difficile infection. Gut Microbes 2011, 2(July-August (4)):252-255.
37. Kotloff K.L., Wasserman S.S., Losonsky G.A., Thomas W., Nichols R., Edelman R., et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001, 69(February (2)):988-995.
38. Sougioultzis S., Kyne L., Drudy D., Keates S., Maroo S., Pothoulakis C., et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005, 128(March (3)):764-770.